menu
    • menu
    [{"orgOrder":0,"company":"Redwire Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"N-(3,4-Dichlorophenyl)-N-methylpropanamide","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Redwire Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Redwire Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Redwire Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ExesaLibero Pharma","sponsor":"SpaceMD","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"N-(3,4-Dichlorophenyl)-N-methylpropanamide","moa":"CYP1A2\/CYP2B6","graph1":"Immunology","graph2":"Preclinical","graph3":"ExesaLibero Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExesaLibero Pharma \/ SpaceMD","highestDevelopmentStatusID":"4","companyTruncated":"ExesaLibero Pharma \/ SpaceMD"}]

    Find Clinical Drug Pipeline Developments & Deals for N-(3,4-Dichlorophenyl)-N-methylpropanamide

    Menu

    N-(3,4-Dichlorophenyl)-N-methylpropanamide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ExesaLibero Pharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ExesaLibero Pharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : N-(3,4-Dichlorophenyl)-N-methylpropanamide

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : SpaceMD

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            SpaceMD Signs Trailblazing Royalty Agreement with ExesaLibero Pharma

                            Details : ExesaLibero Pharma will work with SpaceMD to advance and enhance its groundbreaking small-molecule drug ELP-004 and other relevant compounds via the PIL-BOX system.

                            Product Name : ELP-004

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 04, 2025

                            Lead Product(s) : N-(3,4-Dichlorophenyl)-N-methylpropanamide

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : SpaceMD

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Redwire Corporation

                            Country arrow
                            FNCE
                            Not Confirmed

                            Redwire Corporation

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : N-(3,4-Dichlorophenyl)-N-methylpropanamide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Redwire And Bristol Myers Study Bone Disease Treatments in Space

                            Details : The partnership aims to study model small molecule compounds, including ELP-004, using Redwire’s pharmaceutical drug development platform (PIL-BOX).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : N-(3,4-Dichlorophenyl)-N-methylpropanamide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth